Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2026 08:00 ET | Source: Clene Inc.

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker...
August 15, 2022 07:00 ET | Source: Clene Inc.

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
August 12, 2022 16:01 ET | Source: Clene Inc.

Clene to Host VISIONARY-MS Results Call and Webcast on August 15

SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
June 27, 2022 07:00 ET | Source: Clene Inc.

Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28

SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...